180 related articles for article (PubMed ID: 30156313)
1. Switching biologics in the treatment of psoriatic arthritis in Japan.
Yamamoto T; Ohtsuki M; Sano S; Morita A; Igarashi A; Okuyama R; Kawada A;
J Dermatol; 2019 Mar; 46(3):e113-e114. PubMed ID: 30156313
[No Abstract] [Full Text] [Related]
2. Prevalence and current therapies of psoriatic arthritis in Japan: A survey by the Japanese Society of Psoriasis Research in 2016.
Yamamoto T; Ohtsuki M; Sano S; Igarashi A; Morita A; Okuyama R; Kawada A;
J Dermatol; 2017 Jun; 44(6):e121. PubMed ID: 28256750
[No Abstract] [Full Text] [Related]
3. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Bayaraa B; Imafuku S
J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
[TBL] [Abstract][Full Text] [Related]
4. The confidence of rheumatologists about switching to biosimilars for their patients.
Goll GL; Haavardsholm EA; Kvien TK
Joint Bone Spine; 2018 Oct; 85(5):507-509. PubMed ID: 29631065
[No Abstract] [Full Text] [Related]
5. Epidemiological analysis of psoriatic arthritis patients in Japan.
Yamamoto T; Ohtsuki M; Sano S; Igarashi A; Morita A; Okuyama R; Kawada A;
J Dermatol; 2016 Oct; 43(10):1193-1196. PubMed ID: 26992450
[TBL] [Abstract][Full Text] [Related]
6. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
7. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
[No Abstract] [Full Text] [Related]
8. Comparison of biologics in psoriatic arthritis: an important clinical issue.
Pina Vegas L; Claudepierre P
Rheumatology (Oxford); 2024 May; 63(6):1477-1478. PubMed ID: 37982745
[No Abstract] [Full Text] [Related]
9. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis.
Coates LC; Gossec L; Ramiro S; Mease P; van der Heijde D; Smolen JS; Ritchlin C; Kavanaugh A
Rheumatology (Oxford); 2017 Aug; 56(8):1251-1253. PubMed ID: 28077693
[No Abstract] [Full Text] [Related]
10. Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".
Megna M; Balato A; Napolitano M; Gallo L; Caso F; Costa L; Balato N; Scarpa R
Clin Rheumatol; 2018 Jul; 37(7):1739-1741. PubMed ID: 29644570
[No Abstract] [Full Text] [Related]
11. Treatment strategies for psoriatic arthritis.
Schemoul J; Poulain C; Claudepierre P
Joint Bone Spine; 2018 Oct; 85(5):537-544. PubMed ID: 29155104
[TBL] [Abstract][Full Text] [Related]
12. [Biological agents in treatment of psoriatic arthritis].
Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
[TBL] [Abstract][Full Text] [Related]
13. The approach to precision medicine for the treatment of psoriatic arthritis.
Miyagawa I; Tanaka Y
Immunol Med; 2020 Sep; 43(3):98-102. PubMed ID: 32306849
[TBL] [Abstract][Full Text] [Related]
14. Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine.
Miyagawa I; Nakayamada S; Tanaka Y
Curr Rheumatol Rep; 2019 Mar; 21(5):21. PubMed ID: 30891646
[TBL] [Abstract][Full Text] [Related]
15. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
16. The role of methotrexate in psoriatic arthritis: what is the evidence?
Ianculescu I; Weisman MH
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S94-7. PubMed ID: 26470718
[TBL] [Abstract][Full Text] [Related]
17. Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?
McGonagle DG; Zabotti A; Watad A; Bridgewood C; De Marco G; Kerschbaumer A; Aletaha D
Ann Rheum Dis; 2022 Jan; 81(1):7-10. PubMed ID: 34810194
[No Abstract] [Full Text] [Related]
18. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L; Allen A; Chandler D; Ciurtin C; Dick A; Foulkes A; Gullick N; Helliwell P; Jadon D; Jones G; Kyle S; Madhok V; McHugh N; Parkinson A; Raine T; Siebert S; Smith C; Tillett W; Coates LC
Rheumatology (Oxford); 2022 Aug; 61(9):e255-e266. PubMed ID: 35640657
[No Abstract] [Full Text] [Related]
19. Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire.
Betegnie AL; Gauchet A; Lehmann A; Grange L; Roustit M; Baudrant M; Bedouch P; Allenet B
J Rheumatol; 2016 Apr; 43(4):724-30. PubMed ID: 26879361
[TBL] [Abstract][Full Text] [Related]
20. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
